A molecule that predates blood vessels by hundreds of millions of years, one still found today in creatures as simple as sponges and jellyfish, turns out to play a surprisingly modern role: deciding whether cancer immunotherapy actually works. A study published this week in Nature Communications, from researchers at Nagoya University in Japan, found that a protein called complement C3 can determine how well immune checkpoint drugs perform, but only under one very specific condition that until now had gone entirely unrecognized.

An immune system component older than the immune system we usually think about

The complement system is one of the oldest branches of the immune system, evolutionarily speaking, present in some form across an enormous range of animal life stretching back long before vertebrates developed circulating blood at all. C3 sits at the center of that ancient system, and while researchers have studied complement proteins for decades in the context of infection and inflammation, their specific role inside solid tumors has remained considerably murkier.

The Nagoya University research team, led by lead author Yuki Miyai, an assistant professor at the university's Graduate School of Medicine, set out to clarify exactly what C3 does inside tumor tissue, and more specifically, whether it mattered where in the body that C3 actually came from. "Cancer tumors are surrounded by normal cells called fibroblasts," Miyai explained. "Until now, the role of complement C3 produced by these cancer-associated fibroblasts within tumor tissue was not known."

Two very different sources for the same protein

That question of source turns out to be the entire crux of the discovery. C3 can enter tumor tissue from two fundamentally different origins: it can circulate through the bloodstream after being produced primarily by the liver, the body's main systemic source of complement proteins, or it can be produced locally, directly within the tumor itself, generated by cancer-associated fibroblasts sitting in the immediate tissue surrounding cancer cells.

To determine whether these two sources of the identical protein actually behaved differently, the research team used mouse models specifically designed to separate C3's origin. When C3 produced by the liver was reduced by 90%, a drug that helps the immune system attack tumors, an anti-PD-1 antibody representing the class of checkpoint inhibitor immunotherapy drugs now widely used in cancer treatment, continued working just as effectively as it had before the reduction. That result alone was striking: circulating, liver-derived C3 appeared to have essentially no measurable influence on how well the immunotherapy performed.

Local production tells an entirely different story

The picture changed dramatically when researchers examined C3 produced locally within the tumor tissue itself. According to the study's findings, C3 made specifically within tumor tissue prevents immunosuppressive myeloid cells, a category of immune cells capable of actively weakening the body's ability to mount an effective attack against cancer, from infiltrating into the tumor microenvironment in the first place. With fewer of these suppressive cells accumulating around the tumor, the body's genuine immune defenses had a considerably better opportunity to actually fight the cancer, and checkpoint blockade immunotherapy performed correspondingly better.

The mechanistic pathway researchers identified runs through a specific intermediate step: complement C3 produced locally by cancer-associated fibroblasts restricts immunosuppressive myeloid cell infiltration via a breakdown product called iC3b, a specific cleavage fragment generated when C3 gets processed within tissue. That local iC3b-mediated pathway, rather than C3 concentration in the blood generally, is what the researchers identified as the actual functional driver behind the protein's effect on immunotherapy outcomes.

Higher local C3, better treatment outcomes

Tumors containing fibroblasts that produced more C3 locally showed noticeably fewer immune-suppressing macrophages accumulated within the tumor tissue compared to tumors where local fibroblast C3 production ran lower. That reduced macrophage presence corresponded directly with better outcomes when patients received cancer immunotherapy, establishing local C3 production as what the research team now identifies as a genuinely new factor regulating how effectively checkpoint blockade immunotherapy actually works in a given tumor.

That finding carries real practical weight for cancer treatment, since checkpoint inhibitor immunotherapy, despite transforming outcomes for many cancer patients over the past decade, still fails to work for a substantial share of people who receive it, often because their specific tumor's immune microenvironment remains too actively suppressive for the released immune brakes to translate into genuine anti-tumor activity. Identifying local C3 production as one previously unrecognized factor shaping that suppressive environment gives researchers a concrete new variable to investigate and potentially target directly.

A path toward helping tumors that don't naturally cooperate

Perhaps the most clinically promising implication of the study involves patients whose tumors simply don't produce enough local C3 on their own to generate this protective effect naturally. According to the research team's findings, artificially recreating C3's local protective effect could potentially benefit exactly this group of patients, essentially supplementing a beneficial biological process that their own tumor tissue isn't generating sufficiently by itself.

That approach would represent a meaningfully different therapeutic strategy than simply increasing checkpoint inhibitor dosing alone, since it targets the underlying tumor microenvironment condition making the existing immunotherapy less effective in the first place, rather than attempting to overpower that resistance through the checkpoint drug alone. The researchers describe their next planned steps as testing specific ways of increasing C3 levels locally within tumors and determining the most effective timing for administering any such intervention relative to a patient's existing immunotherapy treatment schedule.

Why an ancient protein's local behavior matters beyond cancer

Beyond its direct relevance to cancer treatment, the research team believes understanding C3's local, tissue-specific activity could illuminate other biological processes entirely separate from cancer immunotherapy, including how the body manages wound healing and regulates inflammation more broadly. Because C3 and the broader complement system evolved so early and remain conserved across such a wide range of species, insights into precisely how local versus systemic complement activity differs functionally could have implications reaching considerably beyond the specific tumor microenvironment context this study examined directly.

What this means for the current gap in immunotherapy effectiveness

Checkpoint inhibitor immunotherapy has reshaped cancer treatment for many patients, but its inconsistent effectiveness, working powerfully for some tumors while barely helping others, remains one of oncology's most persistent unsolved problems. This study adds local C3 production to a growing list of tumor microenvironment factors researchers are working to understand and eventually manipulate therapeutically, alongside other recently identified targets researchers have explored for restoring immune visibility to otherwise resistant tumors.

Whether artificially boosting local tumor C3 production eventually proves safe and effective enough to reach actual clinical use remains to be tested in future research beyond this initial mouse-model study. But the underlying discovery, that where inside the body a molecule gets produced can matter just as much as how much of it exists overall, offers a genuinely useful new lens for understanding why immunotherapy succeeds in some patients and falls short in others, even when their blood tests for the relevant protein might otherwise look identical.

---

*Sources cited in this article include the peer-reviewed study "Local, but not circulating, complement C3 shapes immune checkpoint blockade efficacy by controlling myeloid cell infiltration," published in Nature Communications, and reporting from ScienceDaily, MedicalXpress, News-Medical.net, and AZoLifeSciences covering research led by Yuki Miyai and colleagues at Nagoya University. All figures reflect reporting available as of August 8, 2026.*